Why Africa’s Disease Burden Is Ignored in Global Clinical Trials

A systemic imbalance in global medical research has left African populations severely underrepresented in clinical trials, despite the continent bearing a disproportionate share of the global disease burden. This disparity creates a critical gap in medical knowledge, as treatments developed and tested primarily in high-income countries may not be equally effective or safe for people of African descent.

The disconnect between where diseases are most prevalent and where the research is conducted is often described as a failure of equity in science. While Africa faces high rates of both infectious diseases and a rising tide of non-communicable conditions, the data used to approve new drugs and medical devices is overwhelmingly derived from populations in North America, Europe, and East Asia.

The Burden and the Research Gap

Africa continues to struggle with high incidences of malaria, tuberculosis, and HIV/AIDS, while simultaneously seeing an increase in chronic conditions such as hypertension, diabetes, and various cancers. However, the clinical trials required to optimize treatments for these conditions rarely include sufficient African participants to ensure the results are generalizable.

Reporting from Down To Earth indicates that this bias in medical research means that the specific genetic, environmental, and socioeconomic factors affecting African patients are frequently ignored during the drug development process. This exclusion limits the ability of healthcare providers on the continent to apply evidence-based medicine that is tailored to their specific patient populations.

The lack of representation is not merely a matter of geography but a failure of pharmacogenomics. Genetic diversity is highest in African populations, meaning that the way a drug is metabolized can vary significantly between individuals of African ancestry and those of European or Asian ancestry. When trials lack this diversity, the resulting dosage recommendations or safety profiles may be inaccurate for millions of people.

The Genomic Gap and Precision Medicine

The rise of precision medicine—treatments tailored to a person’s genetic makeup—has further highlighted this inequality. Most genomic databases used to identify disease markers are based on individuals of European descent. This creates a genomic gap that hinders the development of targeted therapies for diseases that disproportionately affect African populations.

For example, certain cardiovascular medications and anticoagulants have shown varying levels of efficacy based on genetic markers that are more common in people of African descent. Without inclusive clinical trials, these differences are often only discovered after a drug has reached the market, leading to suboptimal treatment outcomes or unexpected adverse reactions.

Systemic Barriers to Inclusion

Several structural and historical factors contribute to the exclusion of African participants from global clinical trials. These include:

• Infrastructure Deficits: Many regions lack the specialized clinics, cold-chain storage for experimental drugs, and monitoring equipment required for rigorous phase II and III trials.
• Regulatory Hurdles: Complex and sometimes fragmented regulatory frameworks across different African nations can discourage international pharmaceutical companies from initiating trials.
• Ethical Concerns: A history of medical exploitation and unethical experimentation in Africa has fostered deep-seated mistrust among some populations toward foreign-led medical research.
• Funding Imbalances: Research funding is heavily concentrated in the Global North, with few incentives for companies to invest in trials for diseases that primarily affect low-income populations.

These barriers often lead to a cycle where the lack of data justifies a lack of investment, which in turn ensures that the data gap persists.

The Path Toward Equitable Research

Addressing this bias requires a shift toward decolonizing global health research. Experts argue that rather than simply recruiting African participants for trials designed in the West, there must be an investment in local research capacity. This includes training African scientists, building local trial infrastructure, and empowering national regulatory agencies.

Efforts to increase diversity in clinical trials are beginning to gain traction globally, with some regulators now requiring diversity plans for new drug applications. However, for these policies to be effective in Africa, they must be accompanied by genuine partnerships that ensure the resulting treatments are affordable and accessible to the populations that helped test them.

Without a concerted effort to include African voices and genetics in medical science, the promise of modern medicine will remain unevenly distributed, leaving a significant portion of the global population with treatments that were not designed for them.